The LIGMA assay is established as a viable electrokinetic strategy for improving paper-based biosensors, providing a foundation for expanded applications in clinical diagnostics, multiplexed detection, and portable field-deployable biosensing platforms.
Abstract
Lateral flow assays (LFAs) are widely used for rapid, point-of-care diagnostics but struggle with sensitivity in part due to passive migration and interference from high-abundance serum proteins. Here, we introduce the lateral isotachophoresis-guided migration analysis (LIGMA) assay, a novel diagnostic platform that leverages cationic isotachophoresis (+ITP) to enhance biomolecular separation and detection in LFAs. Using avidin-functionalized gold nanoparticles (AV-S-GNPs) as positively charged nanocarriers, this system enables the direct electrophoretic migration of negatively charged analytes, overcoming a major limitation of conventional cationic electrokinetic focusing methods. The functionalized nanoparticles exhibited superior stability across physiological pH ranges and maintained consistent electrophoretic mobility under + ITP conditions. LIGMA achieved a limit of detection of 1.97 nM and a limit of quantification of 4.12 nM for human immunoglobulin G (IgG), requiring only 1 μL of sample volume and under 2 min of assay time. Compared to standard LFAs, ITP-enhanced migration produced sharper capture line resolution, improved analyte focusing, and minimized background interference from abundant serum proteins. This work establishes the LIGMA assay as a viable electrokinetic strategy for improving paper-based biosensors, providing a foundation for expanded applications in clinical diagnostics, multiplexed detection, and portable field-deployable biosensing platforms.
Lateral flow immunoassay (LFIA) has been widely used for rapid on-site analysis because of its simplicity, portability, and low cost. However, its performance in competitive assays, particularly for small molecule toxins, remains limited, as the properties of antibodies and the reliance on single-mode signal often lead...
Jinzhi Han, Hongzhi Liang, Lin Luo et al.· Biosensors & bioelectronics· 0 citations
This system constitutes, to the authors' knowledge, the first in vitro diagnostic device based on sustainable bio-derived nanoparticles, paving the way for future environmentally friendly tests.
C. Saweres-Argüelles, A. Sánchez-Calvo, Gemma Gutiérrez et al.· Colloids and Surfaces B: Bio...· 0 citations
A dual-mode colorimetric–photothermal LFIA platform was successfully constructed for the detection of thrombosis-related biomarkers, including thrombomodulin and α2-plasmin inhibitor–plasmin complex, in clinical serum samples, enhancing analytical sensitivity and reliability.
Jun Yin, Yu Qiu, Yao Nie et al.· RSC Advances· 0 citations
This programmable dual-aptamer amplified luminescent proximity homogeneous assay (AlphaLISA) provides a rapid, homogeneous, and highly adaptable strategy for tumor-derived sEVs analysis, offering promising potential for noninvasive cancer diagnostics.
Fluorescence-based immunoassays are widely used for sensitive and specific biomarker detection; however, further improvements in sensitivity remain desirable for detecting low-abundance analytes without increasing assay complexity. In this work, we present a proof-of-concept demonstration of guided electrokinetic assem...
Tuo Zhou, Alfonso Shin, L. Kulinsky· Italian National Conference...· 0 citations
A homogeneous fluorescence polarisation immunoassay for the quantification of EVs from whole blood using an antibody tracer using a portable fluorescence polarisation analyser with microfluidic devices to simplify EV quantification after pretreatment.
Hao Liu, M. Fukuyama, Sheng Yuan Leong et al.· Talanta: The International J...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.